Use of RAS pathway activation or KRAS mutation status to predict cetuximab response in CRC patient-derived xenografts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback